# OnCo record pivekimab-sunirine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pivekimab-sunirine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pivekimab-sunirine" ;
  schema:name "Pivekimab sunirine"@en ;
  schema:description "Pivekimab sunirine is an antibody-drug conjugate against CD123, approved in 2026 for blastic plasmacytoid dendritic cell neoplasm as the second targeted drug for this rare cancer."@en ;
  schema:url <https://onco.cc/drugs/pivekimab-sunirine/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pivekimab_sunirine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q139964706> ;
  schema:citation <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "ADC (anti-CD123 antibody, IGN payload)" ;
  schema:alternateName "Decnupaz" ;
  onco:approval "US 2026: Blastic plasmacytoid dendritic cell neoplasm" ;
  onco:cancers <https://onco.cc/cancers/bpdcn/>, <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd123/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:trials <https://onco.cc/trials/nct03386513/>, <https://onco.cc/trials/nct07581002/>, <https://onco.cc/trials/nct04086264/> .